- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Defense Production Act
Insights 10 results
COVID-19 Vaccine Updates
March 2, 2021
White House Invokes the Defense Production Act to Accelerate Johnson & Johnson Vaccine Production
COVID-19 Vaccine Updates
February 9, 2021
February 8 Vaccine Rollout Updates from the White House COVID-19 Response Team
COVID-19 Vaccine Updates
February 9, 2021
FDA Announces Upcoming Guidances for Diagnostic, Therapeutic, and Vaccine Developers
COVID-19 Vaccine Updates
February 9, 2021
White House COVID-19 Response Team Announces Plan to Address Health Equity Concerns with Vaccine Rollout
COVID-19 Vaccine Updates
February 5, 2021
White House COVID-19 Response Team Discusses Use of DPA
COVID-19 Vaccine Updates
February 2, 2021
White House Releases Roadmap for Federal Response to the Pandemic
COVID-19 Vaccine Updates
February 2, 2021
Biden Administration Considers Retrofitting Competitors of Vaccine Manufacturers
COVID-19 Vaccine Updates
January 21, 2021
President Biden Issues Executive Order on Public Health Supply Chain
Client Alert
December 8, 2020
Department of Defense's New Assessment Methodology Takes Effect
Client Alert
June 8, 2020
Criminal and Civil Enforcement of the Defense Production Act